These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 18308560)

  • 1. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
    Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rodent models of treatment-induced motor complications in Parkinson's disease.
    Cenci MA; Ohlin KE
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S13-7. PubMed ID: 20123549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Cenci MA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM
    Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Lundblad M; Picconi B; Lindgren H; Cenci MA
    Neurobiol Dis; 2004 Jun; 16(1):110-23. PubMed ID: 15207268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
    Fulceri F; Biagioni F; Ferrucci M; Lazzeri G; Bartalucci A; Galli V; Ruggieri S; Paparelli A; Fornai F
    Brain Res; 2007 Mar; 1135(1):219-29. PubMed ID: 17222394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.